Press Releases

Date	Title
5/5/21	Sarepta Therapeutics Announces First Quarter 2021 Financial Results and Recent Corporate Developments
5/4/21	Sarepta Therapeutics to Present at Upcoming Investor Conferences
5/3/21	Sarepta Therapeutics Reports Positive Clinical Results from Phase 2 MOMENTUM Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51
4/30/21	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4/30/21	Sarepta Therapeutics to Share Clinical Update for 30 mg/kg arm of MOMENTUM Study for SRP-5051, Its Investigational PPMO for the Treatment of Duchenne Muscular Dystrophy
4/28/21	Sarepta Therapeutics to Announce First Quarter 2021 Financial Results and Recent Corporate Developments on May 5, 2021
4/26/21	Sarepta Therapeutics Statement on April 26, 2021 ICER Commentary Regarding the Accelerated Approval Pathway
4/26/21	Sarepta Recommends Stockholders Reject the Below-Market Mini-Tender Offer by TRC Capital Investment Corporation
3/23/21	Sarepta Therapeutics Announces Fourth Year of Route 79, The Duchenne Scholarship Program
3/18/21	Sarepta Therapeutics’ Investigational Gene Therapy SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E Shows Sustained Expression and Functional Improvements 2 Years After Administration

IR Menu